ARCUTIS BIOTHERAPEUTICS, INC. Proceeds from Common Stock Issued
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Proceeds from Common Stock Issued of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-06-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2024 was $161.68M.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2022 was $161.59M, a 22.12% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 3 month as first filed | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2025-10-28 | $0.00 10-Q · filed 2025-10-28 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $161.68M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2025-10-28 | $161.68M 10-Q · filed 2025-10-28 | $161.68M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $161.68M 10-Q · filed 2025-08-06 | $161.68M derived: sum of 3 quarters · filed 2026-02-25 | $161.68M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $161.70M 10-Q · filed 2026-08-05 | $161.68M 10-Q · filed 2025-05-06 | $161.68M derived: sum of 2 quarters · filed 2026-02-25 | $161.68M derived: sum of 3 quarters · filed 2026-02-25 | $161.68M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-02-28 | $161.70M 10-Q · filed 2026-05-06 | |||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $147.14M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $147.14M derived: sum of 3 quarters · filed 2025-02-25 | $147.14M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $147.14M derived: sum of 2 quarters · filed 2025-02-25 | $147.14M derived: sum of 3 quarters · filed 2025-02-25 | $161.59M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $147.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $147.14M derived: sum of 2 quarters · filed 2023-11-03 | $161.59M 10-Q · filed 2023-11-03 | $161.59M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $14.46M 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2022-08-04 | $14.46M derived: sum of 3 quarters · filed 2024-02-27 | $14.46M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-03-31 | $14.46M 10-Q · filed 2023-05-09 | $0.00 10-Q · filed 2022-05-05 | $14.46M derived: sum of 2 quarters · filed 2024-02-27 | $14.46M derived: sum of 3 quarters · filed 2024-02-27 | $14.46M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $207.49M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $207.49M 10-Q · filed 2022-11-08 | $335.85M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $207.49M 10-Q · filed 2022-08-04 | $335.85M derived: sum of 3 quarters · filed 2023-02-28 | $335.85M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $207.49M 10-Q · filed 2022-05-05 | $335.85M derived: sum of 2 quarters · filed 2023-02-28 | $335.85M derived: sum of 3 quarters · filed 2023-02-28 | $335.85M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $128.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $128.36M derived: sum of 2 quarters · filed 2023-02-28 | $128.36M derived: sum of 3 quarters · filed 2023-02-28 | $128.36M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-22 | |||||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |